|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 1018 |
Guru Rank Value : 0.1 |
Guru Occurances : 4 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
714 |
160,302 |
276,407 |
571,147 |
Total Sell Value |
$64,260 |
$13,335,112 |
$23,824,420 |
$53,365,721 |
Total People Sold |
1 |
5 |
6 |
7 |
Total Sell Transactions |
1 |
11 |
22 |
49 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Baffi Robert |
SVP, Technical Operations |
|
2007-09-14 |
4 |
OE |
$6.13 |
$551,700 |
D/D |
90,000 |
123,124 |
|
- |
|
Baffi Robert |
SVP, Technical Operations |
|
2007-09-14 |
4 |
S |
$22.61 |
$514,015 |
D/D |
(22,707) |
33,124 |
|
- |
|
Aselage Steve |
SVP, Global Commercial Dev. |
|
2007-09-14 |
4 |
S |
$22.40 |
$224,000 |
D/D |
(10,000) |
4,895 |
|
- |
|
Aselage Steve |
SVP, Global Commercial Dev. |
|
2007-09-14 |
4 |
OE |
$7.16 |
$71,600 |
D/D |
10,000 |
14,895 |
|
- |
|
Cooper Jeffrey H |
SVP, Chief Financial Officer |
|
2007-09-06 |
4 |
AS |
$22.50 |
$304,560 |
D/D |
(13,536) |
0 |
|
- |
|
Cooper Jeffrey H |
SVP, Chief Financial Officer |
|
2007-09-06 |
4 |
OE |
$8.10 |
$109,642 |
D/D |
13,536 |
13,536 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2007-08-17 |
4 |
S |
$21.00 |
$210,000 |
D/D |
(10,000) |
6,695 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2007-08-17 |
4 |
OE |
$6.46 |
$64,600 |
D/D |
10,000 |
16,695 |
|
- |
|
Cooper Jeffrey H |
SVP, Chief Financial Officer |
|
2007-08-17 |
4 |
S |
$20.12 |
$405,705 |
D/D |
(20,000) |
0 |
|
- |
|
Cooper Jeffrey H |
SVP, Chief Financial Officer |
|
2007-08-17 |
4 |
OE |
$5.15 |
$132,996 |
D/D |
20,000 |
20,000 |
|
- |
|
Davis George Eric |
VP, General Counsel |
|
2007-08-15 |
4 |
S |
$20.26 |
$81,040 |
D/D |
(4,000) |
2,607 |
|
- |
|
Davis George Eric |
VP, General Counsel |
|
2007-08-15 |
4 |
OE |
$6.13 |
$24,520 |
D/D |
4,000 |
6,607 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2007-08-10 |
4 |
S |
$21.08 |
$55,504 |
D/D |
(2,633) |
0 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2007-08-10 |
4 |
OE |
$6.13 |
$22,278 |
D/D |
2,633 |
2,633 |
|
- |
|
Lewis Alan |
Director |
|
2007-08-10 |
4 |
S |
$20.00 |
$401,633 |
D/D |
(20,000) |
10,000 |
|
- |
|
Lewis Alan |
Director |
|
2007-08-10 |
4 |
OE |
$7.72 |
$231,600 |
D/D |
30,000 |
30,000 |
|
- |
|
Aselage Steve |
SVP, Global Commercial Dev |
|
2007-08-10 |
4 |
S |
$20.21 |
$405,389 |
D/D |
(20,000) |
4,895 |
|
- |
|
Aselage Steve |
SVP, Global Commercial Dev |
|
2007-08-10 |
4 |
OE |
$7.16 |
$143,200 |
D/D |
20,000 |
24,895 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2007-08-10 |
4 |
S |
$20.20 |
$724,917 |
D/D |
(35,886) |
6,695 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2007-08-10 |
4 |
OE |
$6.46 |
$231,824 |
D/D |
35,886 |
42,581 |
|
- |
|
Cooper Jeffrey H |
SVP, Chief Financial Officer |
|
2007-08-08 |
4 |
AS |
$21.00 |
$262,500 |
D/D |
(12,500) |
0 |
|
- |
|
Cooper Jeffrey H |
SVP, Chief Financial Officer |
|
2007-08-08 |
4 |
OE |
$8.10 |
$101,250 |
D/D |
12,500 |
12,500 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2007-08-03 |
4 |
AS |
$18.00 |
$36,053 |
D/D |
(2,000) |
6,695 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2007-07-05 |
4 |
AS |
$18.21 |
$36,582 |
D/D |
(2,000) |
8,695 |
|
- |
|
Swiedler Stuart J |
SVP, Clinical Affairs |
|
2007-07-02 |
4 |
AS |
$18.09 |
$227,203 |
D/D |
(12,500) |
10,000 |
|
- |
|
1213 Records found
|
|
Page 44 of 49 |
|
|